July 11: The Week in Cancer News
Steroids at the start of immunotherapy can negatively affect response, and colorectal cancer may lead to sexual side effects in women.
Progress Against Cancer
Steroids at the start of immunotherapy can negatively affect response, and colorectal cancer may lead to sexual side effects in women.
New AI-driven models unveiled at the AACR Annual Meeting 2025 could revolutionize how we diagnose sarcomas in children.
Study found teclistamab-cqyv, an immunotherapy, led to responses in patients with high-risk, heavily pretreated multiple myeloma, including after prior BCMA therapy. Teclistamab-cqyv (Tecvayli), a type of immunotherapy, received accelerated approval from the U.S. Food...
‘Practice-changing’ research shows adding immunotherapy before and after surgery reduced recurrences for early-stage gastric cancer.
Uterine cancer diagnoses expected to climb in the next 25 years, and some disposable e-cigarettes emit more carcinogens than traditional cigarettes.
The FDA has approved sunvozertinib for certain patients with EGFR-mutated non-small Cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sunvozertinib (Zegfrovy) for the treatment of adult patients...
The FDA has approved linvoseltamab-gcpt for certain patients with heavily pretreated multiple myeloma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with...
Incidence-based mortality is also projected to increase with disproportionately higher rates for Black women compared with white women. Incidence and mortality rates for most cancer types have been on the decline in the United...
Participating in a structured exercise program after treatment was associated with a reduced risk of recurrence in people who had colon cancer.
A single-cell atlas helped clarify diverse forms of acute myeloid leukemia, with potential implications for improving diagnostic, prognostic, and therapeutic capabilities.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More